Citadel Advisors
ATNM icon

Citadel Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

Citadel Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,200
Closed -$9.98K – 12473
2025
Q1 		$9.98K Buy
6,200
+1,400
+29% +$1.78K ﹤0.01% 13565
2024
Q4 		$6.05K Sell
4,800
-16,900
-78% -$26.2K ﹤0.01% 13822
2024
Q3 		$40.8K Sell
21,700
-9,300
-30% -$36.7K ﹤0.01% 12131
2024
Q2 		$229K Sell
31,000
-4,100
-12% -$33.8K ﹤0.01% 9643
2024
Q1 		$275K Sell
35,100
-1,000
-3% -$6.43K ﹤0.01% 9652
2023
Q4 		$183K Sell
36,100
-20,200
-36% -$104K ﹤0.01% 10078
2023
Q3 		$333K Sell
56,300
-13,900
-20% -$92.5K ﹤0.01% 8954
2023
Q2 		$521K Sell
70,200
-5,100
-7% -$43.4K ﹤0.01% 7847
2023
Q1 		$712K Buy
75,300
+12,500
+20% +$132K ﹤0.01% 7527
2022
Q4 		$669K Buy
62,800
+23,700
+61% +$241K ﹤0.01% 7642
2022
Q3 		$289K Sell
39,100
-1,000
-2% -$6.22K ﹤0.01% 9660
2022
Q2 		$193K Buy
40,100
+14,200
+55% +$80.6K ﹤0.01% 10733
2022
Q1 		$132K Sell
25,900
-6,100
-19% -$32.1K ﹤0.01% 11991
2021
Q4 		$192K Buy
32,000
+10,700
+50% +$80.3K ﹤0.01% 11898
2021
Q3 		$189K Sell
21,300
-11,400
-35% -$79.3K ﹤0.01% 12065
2021
Q2 		$259K Buy
32,700
+15,000
+85% +$118K ﹤0.01% 11621
2021
Q1 		$135K Sell
17,700
-43,900
-71% -$373K ﹤0.01% 12165
2020
Q4 		$480K Buy
61,600
+41,600
+208% +$452K ﹤0.01% 8216
2020
Q3 		$194K Buy
+20,000
New +$221K ﹤0.01% 8831
2018
Q4 		– Sell
-333
Closed -$7K – 9075
2018
Q3 		$7K Buy
+333
New +$6.78K ﹤0.01% 9121
2016
Q1 		– Sell
-427
Closed -$41K – 6743
2015
Q4 		$41K Buy
427
+10
+2% +$665 ﹤0.01% 7455
2015
Q3 		$22K Buy
+417
New +$27.9K ﹤0.01% 8089

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's ATNM Position: Q4 2025 in Review

Citadel Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q4 2025, closing a stake of 126,615 shares — an estimated $185K sold.

Citadel Advisors first reported a position in ATNM in Q2 2015 and held it in 27 quarters. The position peaked at $1.29M in Q4 2022. 60 funds tracked by Wall St. Rank hold ATNM as of Q4 2025.

  • Citadel Advisors reported no remaining Actinium Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 126,615 Actinium Pharmaceuticals shares in Q4 2025, an estimated $185K.
  • Citadel Advisors first reported a position in Actinium Pharmaceuticals in Q2 2015 and held it in 27 quarters.
  • Citadel Advisors's Actinium Pharmaceuticals position peaked at $1.29M in Q4 2022.
  • 60 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.